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Nowadays, we are experiencing the big data era with the emerging challenge of single
data interpretation. Although the advent of high-throughput technologies as well as
chemo- and bio-informatics tools presents pan-omics data as the way forward to
precision medicine, personalized health care and tailored-made therapeutics can be
only envisaged when interindividual variability in response to/toxicity of xenobiotics
can be interpreted and thus, predicted. We know that such variability is the net
outcome of genetics (host and microbiota) and environmental factors (diet, lifestyle,
polypharmacy, and microbiota) and for this, tremendous efforts have been made to
clarify key-molecules from correlation to causality to clinical significance. Herein, we
focus on the host–microbiome interplay and its direct and indirect impact on efficacy and
toxicity of xenobiotics and we inevitably wonder about the role of viruses, as the least
acknowledged ones. We present the emerging discipline of pharmacometabolomics-
informed viromics, in which pre-dose metabotypes can assist modeling and prediction
of interindividual response to/toxicity of xenobiotics. Such features, either alone or in
combination with host genetics, can power biomarker discovery so long as the features
are variable among patients, stable enough to be of predictive value, and better than
pre-existing tools for predicting therapeutic efficacy/toxicity.
Keywords: pharmacometagenomics, pharmacometabolomics, pharmacogenomics, precision medicine,
viromics, metagenomics
INTRODUCTION
Complex interactions between the host immune system and microbiota are of dynamic nature
and hence, of fundamental importance when homeostasis is considered, as the host is exposed to
trillions of indigenous microorganisms; bacteria, archaea, fungi, and viruses (Hooper et al., 2012;
Virgin, 2014) (Figure 1). Metagenomics data suggest that the microbiome of healthy humans
includes several viral genes and the intestines and skin of healthy individuals are associated
with viruses that replicate in eukaryotic and prokaryotic cells (Reyes et al., 2010). Temperate
bacteriophages, which are assembled and propagated stably within the bacterial host chromosome,
are considered as the predominant viral group (Reyes et al., 2010; Minot et al., 2013). Plant-
infecting viruses, herpesviruses, poxviruses and picornaviruses are less abundant and often derived
from diet (Kim et al., 2011). Yet, the great majority of viruses remains unidentified (Minot et al.,
2012a,b; Reyes et al., 2012) and much less is known about the role of resident viruses.
We believe in a systems-level understanding of the host–microbiome interplay and its impact
on the efficacy/toxicity of xenobiotics with an emphasis on resident viruses, as their diversity,
abundance and role is still poorly understood. Herein, we wonder about the role of viruses, as
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FIGURE 1 | Omics strategies complement each other to address current challenges. Metagenomics aims to address the question of “which entities are
present?” via high-throughput sequencing or microarrays. Recently, culturomics has been introduced as a complementary approach to metagenomics. Viromics
(viral metagenomics) studies aim to identify resident viruses. Metatranscriptomics and metaproteomics focus on “which entities are active?” Pharmacometabolomics
(the later term used synonymously with pharmacometabonomics), pharmacogenomics and pharmacometagenomics aim to predict the response to and/or toxicity
of xenobiotics on the basis of pre-dose profiling.
the least acknowledged ones and we present the emerging
discipline of pharmacometabolomics-informed viromics, in
which pre-dose metabotypes (metabolic phenotypes) can assist
modeling and prediction of interindividual variability in response
to/toxicity of xenobiotics. Such features, either alone or in
combination with host genetics, can power biomarker discovery
so long as the features are variable among patients, stable enough
to be of predictive value, and better than pre-existing tools for
predicting therapeutic efficacy/toxicity.
Horizontal Genetic Transfer Results in
Evolutionary Changes and Confers
Interindividual Variability
Viral–microbial interactions in the human gut seem to be rather
different from the predator-prey relationship that is known as
“kill the winner” and dominates in other ecosystems (Reyes
et al., 2010). Horizontal genetic transfer occurs frequently among
gut microbes (Roberts et al., 2008; Tamames and Moya, 2008).
Viruses, particularly bacteriophages, are one of the main drivers
of the evolutionary change seen in microorganisms through
horizontal genetic transfer. The observation that gut microbial
metagenomes consist of a large number of phage-related genes
implies a viral role in gut homeostasis (Qin et al., 2010). In
healthy gut, viruses may elicit innate immune responses. Pattern-
recognition receptors can detect viral components (Takeuchi and
Akira, 2010) and initiate the crosstalk between resident viruses
and the innate immune system. Commensal bacteria-depleted
mice have been reported to recover from severe gut inflammation
upon administration of lipoteichoic acid or lipopolysaccharide,
implying that toll-like receptors have a protective role that
extends beyond the recognition of commensal bacteria to other
microbes (Rakoff-Nahoum et al., 2004). Resident gut viruses have
reduced inflammation via toll-like receptor 3- and 7-mediated
interferon-beta production, shedding light for the first time
on the interplay of host innate immune system and viruses
(Yang et al., 2016). Horizontal genetic transfer confers increased
pathogenicity, antibiotic resistance and new metabolic activity
(Reyes et al., 2010; Minot et al., 2011). Therefore, bacteriophages
are of biomedical importance.
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Within-Individual and Inter-individual
Viral Evolution
Metagenomic data emphasize that bacterial strains are
significantly different among individuals, although their gut
typically contains bacteria from only a few phyla (Turnbaugh
et al., 2009). Different body sites are also inhabited by different
bacterial strains (Peterson et al., 2009; Blaser, 2010; Chen et al.,
2010; Qin et al., 2010). This variation may account for their
highly variable phage predators, as phages can be highly selective
(Rodriguez-Valera et al., 2009). Notably, phage sensitivity is
used in the clinic to distinguish bacterial strains (Sell et al.,
1983; Mahony et al., 1991). Furthermore, the great variability
reported in phage populations among individuals may come
from within-individual viral evolution, when long-term viral
residents are considered. Rapid within-host viral evolution has
been reported, suggesting that multiple new viral species arise
in the gut of a typical human over the course of human life
(Minot et al., 2013). Notwithstanding, the forces diversifying
bacteriophage genomes in human hosts have not been studied in
detail.
We strongly feel that changes in abundance and composition
of microbiota (dysbiosis) underline interindividual variability.
That said, gut microbiota and particularly, resident viruses
have not been a focus for the drug metabolism and toxicology
communities, despite several early studies showing their
importance in xenobiotic biotransformation (Boxenbaum
et al., 1979; Illing, 1981). Notwithstanding, re-evaluation and
awareness are critical, as microbiota represent a source of
physiological variability among individuals and populations that
can readily affect the disposition and toxicity of xenobiotics and
their metabolites. These effects can be direct or indirect (Nayak
and Turnbaugh, 2016). Indirect effects include the metabolic
exchange and the co-metabolism and processing of endogenous
and dietary substrates (Nicholson and Wilson, 2003). Gut
microbiome can alter the expression of host’s pharmacogenes
(Björkholm et al., 2009). Microbiome-derived metabolites have
been reported to modulate the drug metabolizing systems of
the host (Wilson and Nicholson, 2016). Orally administered
xenobiotics are exposed to gut microbes prior to their absorption
and hence, their bioavailability and half-life is altered (Al-Hilal
et al., 2013). The compositional and/or functional alterations
in gut microbiota brought about by polypharmacy or the
administration of antibiotics, probiotics, or prebiotics greatly
increase interindividual variability in response to xenobiotics (Li
and Jia, 2013). Notably, the role of resident viruses is still poorly
understood.
CHALLENGES AND OPPORTUNITIES
If microbiome in total has escaped our full attention so far,
resident viruses in humans and animals are poorly acknowledged
today. Even though viruses are extremely important to the
ecology (Roossinck, 2015; Puxty et al., 2016), the discipline of
viromics (or viral metagenomics, as it is used interchangeably)
can be currently considered as the most elusive of the -omics
fields.
“WHICH ENTITIES ARE PRESENT?”
The human body is a host for a complex living microbial
community consisting of bacteria, archaea, fungi, protozoa and
viruses, which together constitute the human microbiota. The
total genome of microorganisms is also the human metagenome
and hence, metagenomic studies aim to address the question
of “which entities are present?” via high-throughput sequencing
or microarrays. Technical challenges are still profound, when
seeking for an answer to that question (Figure 1).
Viruses outnumber microbial cells 10:1 in most environments,
yet, viral DNA only represents 0.1% of the total DNA in a
microbial community, such as the human gut (Qin et al., 2010).
If a deep sequence coverage of the human viruses is desired,
viral particles should be isolated (Reyes et al., 2010; Hurwitz
et al., 2013). As the amount of the nucleic acids extracted from
purified viral particles is often below the required threshold for
sequencing, several amplification methods have been developed;
random amplified shotgun library (Rohwer et al., 2001), linker-
amplified shotgun library (Breitbart et al., 2003) and multiple
displacement amplification (Hutchison et al., 2005) are a few
examples. The latter method is greatly advantageous, as it allows
the amplification of complete viral genomes, although recent
reports have implied that critical biases and contamination is an
issue (Zhang et al., 2006; Yilmaz et al., 2010).
Today, the majority of the viral sequences are novel or
enriched in regions of low-complexity repeats. Thus, sequencing
technologies that prioritize long-read lengths over those of short-
read lengths are preferred (Wommack et al., 2008). However,
sequencing technologies of long-read lengths, such as 454/Roche
pyrosequencing, are about to be discontinued (Bikel et al., 2015).
Bioinformatics tools that have been developed to analyze viruses
from short sequence reads have accepted this challenge (Liu et al.,
2007). Moreover, the majority (usually, 60–99%) of the viral
sequences studied so far have no significant similarity to other
sequences in databases or have higher homology to prokaryotic
or eukaryotic genes (Breitbart et al., 2002, 2003; Blomström
et al., 2010). A crucial step in viromics is the filtering of bad
quality sequences or the decontamination of 16S rRNA, 18S
rRNA and human sequences by mapping. Mapping algorithms
or tools, such as ViroBLAST (Deng et al., 2007), BLASTX (Segata
et al., 2012) or USEARCH (Edgar, 2010) are employed to obtain
the taxonomic composition of a viral community. Taxonomic
and functional assignments are crucial for the viral community
profile to be created, since it reflects sample diversity. Today, the
number of the deposited genomes in databases is far less than
the expected number of virotypes (Rohwer and Thurber, 2009),
while most of the new sequences are poorly annotated (Brister
et al., 2014; Martınez et al., 2014). The percentage of sequence
reads with similarity to known viral sequences depends on the
database used and on how well sequences have been filtered.
This percentage is less than 0.01% (Yang et al., 2011; Bikel et al.,
2015). MetaVir, VIROME, and iVirus are few publicly available
databases (Sullivan, 2015).
To assist viromics data analysis similarity-independent
methods have been also developed. PHACCS assesses the
biodiversity of uncultured viral communities and quantifies
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virotypes (Breitbart et al., 2002; Angly et al., 2005) and CRASS
allows the simultaneous cross-assembly of all the samples in a
dataset to identify shared viruses (Dutilh et al., 2012). MaxiPhi
uses pairwise assemblies from pooled viromes (Angly et al., 2005).
To tackle chimeras, the overlap–layout–consensus algorithms
have achieved the assembly of viral genomes. Newbler has been
extensively used in viral and bacterial shotgun metagenomic
projects (Qin et al., 2010; Reyes et al., 2010; Bikel et al., 2015). Yet,
it remains to be determined, if Newbler will be discontinued with
the 454/Roche in 2016 (Bikel et al., 2015). Minimo is designed
for the assembly of small datasets (Treangen et al., 2011) and
VICUNA is an assembler that is specialized in de novo assembly
of data from heterogeneous viral populations (Yang et al., 2012).
MetaVelvet (Namiki et al., 2012) and other de Brujin graph
assemblers are an alternative to the overlap–layout–consensus
assemblers and have also been used on the assembly of viral
genomes (Hurwitz and Sullivan, 2013). Sequencing of total RNA
viruses has been proven impractical (Robertson et al., 2010).
“WHICH ENTITIES ARE ACTIVE?”
One might have already thought that this question is even more
difficult to address. We share an optimistic view on the basis
of the metatranscriptomic, metaproteomic and metabonomic
studies being reported (Lim et al., 2013; Aguiar-Pulido et al.,
2016; Yu et al., 2016). The NIH-sponsored Human Microbiome
Project has been established to comprehensively characterize
human microbiota from multiple body sites and analyze their
impact in human health and disease (Peterson et al., 2009;
Proctor, 2016). The Vaginal Human Microbiome Project has
validated a protocol that achieves species-level classification
of V1–V3 16S rRNA sequence from the vaginal microbiome
(Fettweis et al., 2012). Culturomics, coupled to matrix-assisted
laser desorption/ionization time-of-flight (MALDI-TOF) mass
spectrometry, has been also introduced as complementary
to metagenomics to study complex microbial ecosystems,
such as the human gut. Lagier et al. (2012) provided a
proof-of-concept applying 212 different culture conditions and
successfully culturing 340 different bacterial species, five fungi
and for the first time, Senegalvirus (Greub, 2012; Lagier
et al., 2012). Dubourg et al. (2014) coupled culturomics with
pyrosequencing to address the effect of antibiotics in gut
microbiota diversity (Dubourg et al., 2014). Yet, resident viruses
and their interplay with the host (human or other microbes) are
poorly studied.
“WHICH ENTITIES ARE PREDICTIVE OF
RESPONSE TO/TOXICITY OF
XENOBIOTICS?”
Every human being is unique and microbiota that colonize the
human body shape individuality to a great extent. Interindividual
variability is a prerequisite to tailored-made therapeutics
and personalized health care. A systems-level understanding
is required to delineate the host–microbiota interplay. The
advent of high-throughput technologies and bio- and chemo-
informatics tools presents pan-omics approaches as the way
forward. Can we predict xenobiotics efficacy/toxicity by pre-dose
profiling?
Traditionally, the host has been our focus, embracing the
potential of pharmacogenomics and pharmacometabolomics.
Pharmacogenomics has pioneered the prediction of the outcome
of a xenobiotic intervention in an individual based on an
analysis of that individual’s genetic profile (Smalley and Sondak,
2010; Ritchie, 2012; Hershfield et al., 2013; Everett, 2015).
Today, FDA-approved drug labeling may contain information
on pharmacogenomic biomarkers. The U.S. National Human
Genome Research Institute and the National Academy of
Medicine recently brought together 25 innovative genomic
medicine programs to coalesce innovative genomic medicine
programs around concrete and at the same time, compelling
signature projects accelerating the responsible implementation of
genomic medicine in efforts to improve clinical care worldwide
(Manolio et al., 2015). Pharmacometagenomics are anticipated to
perform an analogous task to that of pharmacogenomics focusing
on human metagenome (the total genome of microorganisms).
Indeed, a more mechanistic understanding of which microbes
and genes contribute to xenobiotics efficacy/toxicity may enable
prediction of which patients will derive greatest benefit from
a therapeutic intervention (Haiser et al., 2013; Nayak and
Turnbaugh, 2016). Pharmacometabolomics is predictive of
the outcome of a xenobiotic intervention in an individual
based on a mathematical model of pre-intervention metabolite
signatures (Nicholson et al., 1999; Clayton et al., 2006).
Pharmacometabolomics is based on metabotypes, as they are the
net result of genetic, physiological, chemical, and environmental
influences (Holmes et al., 2008; Everett, 2015). Recently,
a new concept has arisen, namely “pharmacometabolomics-
aided pharmacogenomics,” to reinforce the identification and
validation of clinically relevant associations (Ji et al., 2011; Suhre
et al., 2011; Abo et al., 2012). We have recently proposed that
pharmacometabolomics-aided pharmacogenomics may have an
even greater impact if coupled to information technologies to
facilitate data analysis and sense- and decision-making on the
basis of a synergy between artificial and human intelligence
(Katsila et al., 2016).
If we want to turn information growth into knowledge
growth and better informed decisions, the implementation of
new working practices is more than necessary. A paradigm
may well be pharmacometabolomics-informed viromics. In an
analogy to pharmacometabolomics-aided pharmacogenomics,
pharmacometabolomics-informed viromics benefits from pre-
dose metabotypes that can assist modeling and prediction
of interindividual response to and/or toxicity of xenobiotics,
this time not focusing on the host, but on the resident
viruses and their interactions. Although bacteria have been
directly associated with dysbiosis and interindividual variability
upon xenobiotics administration, the role of the virome in
the microbial community should be further explored. So
far, scientists have been focusing on the “which entities are
present?” and “which entities are active?” questions with the
aim to address the “which entities are predictive of response
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to/toxicity of xenobiotics?” challenge. Instead, we suggest a
global focus on metabolites as the biochemical end points of
complex interactions between the host and its environment
(including the gut microbiome). Thus, a global readout
will be revealed mapping microbial, viral and mammalian
interindividual variability upon xenobiotics administration. Our
next step is to integrate phenotypic and genotyping approaches
with information technologies.
Instead of any single omics approach, we propose an
integrated (transomic) analysis that is anticipated to provide
more insights into the emergence of the phenotypes in question
(response to/toxicity of xenobiotics) than any layer can by itself,
highlighting the complementarity of a multilayered strategy.
In this context, we have two layers of systems-scale molecular
measurements; the pharmacometabolome (layer 1) and the
virome (layer 2; Figure 2). Layer 1 characterization includes
sample acquisition and preparation, analysis (NMR or mass
spectrometry technologies), data processing and data analysis
(targeted and untargeted). Particularly, untargeted analysis is of
great benefit as a tool to shape hypothesis; multiple analytes are
quantified simultaneously and pharmacometabolomic modeling
is not limited by prior understanding or hypotheses. Such
metabotype-based findings may be patient and/or xenobiotic
profiling. MALDI-TOF mass spectrometry has recently enabled
spatial information. Dorrestein’s methodologies aim to scan
microbial communities, capture their exact image and identify
what microorganisms do in their complex communities by
identifying and locating the metabolites produced (Tullis, 2016).
Pirhaji et al. (2016) reported PIUMet, a network-based approach,
prize-collecting Steiner forest algorithm for integrative analysis
of untargeted metabolomics (Pirhaji et al., 2016). PIUMet infers
molecular pathways and components via integrative analysis of
metabolite features, without requiring their identification. If a
hypothesis is already in place, targeted pharmacometabolomics
is advantageous (Williams et al., 2016). Then, viromics (layer 2)
is performed as of today. VirCapSeq-VERT is ideally suited for
the analysis of virome composition and dynamics, as its highly
multiplexed nature allows the simultaneous identification and
comprehensive genetic characterization of all known vertebrate
viruses and their genetic variants as well as the novel ones
(Briese et al., 2015). Similarly, quantitative temporal viromics
are applied to a wide range of viruses (Weekes et al., 2014).
At this point, transomic data sets are generated that consist of
pharmacometabolomics (layer 1) and viromics (layer 2) data.
We propose in-depth data mining, analysis and argumentation,
according to which information technologies provide the
means for filtering and systems-level dynamic parameters from
fewer samples across broad molecular interaction networks.
Data mining, analysis, collaboration and decision-making in
such diverse data-intensive and cognitively complex settings is
performed via the Dicode approach, supporting artificial and
human intelligence (the Dicode platform and services provide
a remedy to the information and cognitive overload as users
can customize the Dicode workbench via a proper assembly of
tools that suit their needs and properly structured data lead to
more informed decisions). The envisioned architecture combines
FIGURE 2 | A pharmacometabolomics-informed viromics workflow – the overall multilayered strategy. Instead of any single omics approach, we propose
an integrated (transomic) analysis. In this context, we have two layers of systems-scale molecular measurements; the pharmacometabolome (layer 1) and the virome
(layer 2). Layers 1 and 2 are coupled to information technologies.
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batch and stream processing (Karacapilidis, 2013; Tsiliki et al.,
2014). Current limitations, such as lack of annotation, lack
of a conserved region in the virome and/or “non-cultivable”
viral entities are by-passed. Viral–microbiota–host–xenobiotics
relationships are revealed and modeled following a multilayered
approach.
CONCLUSION AND FUTURE
PERSPECTIVES
Microbiota in humans is a collection of microscopic
organisms that inhabit the body and contains representatives
from all the domains of life: archaea, bacteria, eukarya,
viruses. If interindividual variability in response to and/or
toxicity of xenobiotics is to be acknowledged, viral–
microbial–host–xenobiotics dynamics need to be further
clarified. Pharmacometabolomics-informed viromics coupled
to information technologies highlight the complementarity
of a multilayered approach to turn information growth into
knowledge growth.
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